01756nas a2200337   4500000000100000008004100001260001300042653002300055653003000078653002400108653001100132653002300143653001200166653001800178100001200196700002200208700001500230700001500245700001500260700001200275700001600287700001600303700001500319245016800334856005900502300001100561490000700572050003200579520079300611022001401404       1993                            d  c1993 Dec10aBacterial Vaccines10aCombined Modality Therapy10aDouble-Blind Method10aHumans10aLeprostatic Agents10aleprosy10aMycobacterium1 aWalia R1 aSarathchandra K G1 aPandey R M1 aParida S K1 aZaheer S A1 aKar H K1 aMukherjee A1 aMukherjee R1 aTalwar G P00aField trials on the use of Mycobacterium w vaccine in conjunction with multidrug therapy in leprosy patients for immunotherapeutic and immunoprophylactic purposes.  uhttp://leprev.ilsl.br/pdfs/1993/v64n4/pdf/v64n4a03.pdf  a302-110 v64  aInfolep Library - available3 a<p>A double blind field trial was started with a candidate anti-leprosy vaccine, Mycobacterium w as an immunotherapeutic and immunoprophylactic agent against leprosy in a highly endemic region with a prevalence rate of over 18 per 1000 population. By 31 August 1992, 224 villages have been surveyed, covering a population of 307,981 (1981 census). A total of 979 MB patients and 2801 PB patients have been registered. A total of 19,453 household contacts of leprosy patients have been examined for clinical signs of disease, of which 16,519 have received the initial dose while 10,434 have also received the booster dose of vaccine/placebo. The aims and objectives, study design of the trial, present status as well as the socio-cultural aspect involved are highlighted in this paper.</p>  a0305-7518